The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.
Kirollos Hanna, PharmD
Advertisement
Articles by Kirollos Hanna, PharmD
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Advertisement
Latest Updated Articles
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos HannaPublished: January 25th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
3
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
4
Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting
5
